The Animal Health segment reported revenues of $981.0 million in 4Q17.
The Gardasil franchise reported total sales of $633.0 million in 4Q17, representing 17.0% growth compared to $542.0 million in 4Q16.
Remicade reported revenues of $186.0 million in 4Q1 for a 31.0% decline compared to revenues of $269.0 million in 4Q16.
Januvia reported revenues of $938.0 million in 4Q17 for 1.0% growth compared to revenues of $932.0 million in 4Q16.
Keytruda (pembrolizumab) is Merck & Co.’s (MRK) top-selling drug, with revenues of ~$1.3 billion in 4Q17.
For 4Q17, Keytruda reported revenues of ~$1.3 billion for 169.0% growth compared to revenues of $483.0 million in 4Q16.
Merck & Co.’s (MRK) revenues reported 3.0% growth in revenues to ~$10.4 billion in 4Q17.
Merck & Co. (MRK) reported 3.0% revenue growth to ~$10.4 billion in 4Q17 compared to $10.1 billion in revenues in 4Q16.
Let’s now look at how capacity expansion could translate into cannabis companies’ margins.
The upcoming legalization of recreational cannabis in Canada has led investors to pour money into cannabis producers such as Canopy Growth (WEED), Aphria (APHQF), Aurora Cannabis (ACBFF), and MedReleaf (MEDFF).
On February 14, Canopy Growth reported its fiscal 3Q18 results. The company saw quarterly revenues of 21.7 million Canadian dollars, an increase of almost 123% from 3Q17.
There could possibly be a ceiling on cannabis prices for producers such as Canopy Growth (WEED), Cronos (PRMCF), Aphria (APHQF), and Aurora Cannabis (ACBFF), which could eventually put pressure on margins.
In Alberta, the retail stores will be privately run, but these retailers will receive their product from a government-regulated distributor.
While cannabis stocks are trading lower year-to-date, investment activity in the cannabis industry continues to grow.
In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a key collaboration agreement.
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
Medtronic (MDT) plans to release its 3Q18 earnings results on February 20, 2018.
On February 20, 2018, Medtronic (MDT) is set to announce its 3Q18 earnings results.
Medtronic (MDT) plans to announce its 3Q18 earnings results on February 20.
In the fiscal year 2017, Pfizer’s (PFE) LEP (Legacy Established Products) segment reported net revenues of $10.89 billion, compared with $11.20 billion in 2016. In 2017, in the US and outside…